Why Shares in Arcutis Biotherapeutics Surged Again This Week

The company continues to receive good news from the Food and Drug Administration.
Glamour

How to Treat Dry Patches on Skin, According to a Dermatologist

There are a few ingredients that can help treat dry patches. “I advise patients to look for products that contain hyaluronic ...
The American Journal of Managed Care

Seborrheic Dermatitis Linked to Higher Risk of Epithelial Barrier Diseases

Seborrheic dermatitis may be linked to various epithelial barrier diseases (EBDs) affecting multiple organ systems and ultimately a key factor when addressing epithelial barrier weakness and ...

Seborrheic dermatitis: Large US cohort reveals pattern of epithelial barrier disease overlap

Researchers at the Perelman School of Medicine at the University of Pennsylvania report that adults with seborrheic ...
Northern Ontario Business

North Bay natives launch breakthrough Canadian medicated shampoo with 2 per cent zinc pyrithione

The new Freedom Medicated Shampoo developed by their family-run Freedom Clinic Toronto is the first and only shampoo on the ...

Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages ...

Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in child ...

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5

Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical ...